JP2008510493A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008510493A5 JP2008510493A5 JP2007530107A JP2007530107A JP2008510493A5 JP 2008510493 A5 JP2008510493 A5 JP 2008510493A5 JP 2007530107 A JP2007530107 A JP 2007530107A JP 2007530107 A JP2007530107 A JP 2007530107A JP 2008510493 A5 JP2008510493 A5 JP 2008510493A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- adenovirus
- tre
- cell
- tumor cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000203 mixture Substances 0.000 claims 32
- 210000004881 tumor cell Anatomy 0.000 claims 19
- 108700029229 Transcriptional Regulatory Elements Proteins 0.000 claims 15
- 241000701161 unidentified adenovirus Species 0.000 claims 15
- 108091026890 Coding region Proteins 0.000 claims 10
- 210000004027 cell Anatomy 0.000 claims 8
- 101710145505 Fiber protein Proteins 0.000 claims 6
- 241000124008 Mammalia Species 0.000 claims 5
- 150000001413 amino acids Chemical class 0.000 claims 5
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 claims 3
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims 3
- 230000037430 deletion Effects 0.000 claims 3
- 238000012217 deletion Methods 0.000 claims 3
- 230000010076 replication Effects 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 108010027410 Adenovirus E3 Proteins Proteins 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 208000037841 lung tumor Diseases 0.000 claims 2
- 101710201734 E3 protein Proteins 0.000 claims 1
- 101000578784 Homo sapiens Melanoma antigen recognized by T-cells 1 Proteins 0.000 claims 1
- 101000961414 Homo sapiens Membrane cofactor protein Proteins 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 102100031413 L-dopachrome tautomerase Human genes 0.000 claims 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims 1
- 102100028389 Melanoma antigen recognized by T-cells 1 Human genes 0.000 claims 1
- 102100039373 Membrane cofactor protein Human genes 0.000 claims 1
- 101100228942 Mus musculus Gldn gene Proteins 0.000 claims 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 claims 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 claims 1
- 101710138647 Protein tyrosine phosphatase type IVA 3 Proteins 0.000 claims 1
- 102100024601 Protein tyrosine phosphatase type IVA 3 Human genes 0.000 claims 1
- 108010017842 Telomerase Proteins 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 claims 1
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 claims 1
- 230000000735 allogeneic effect Effects 0.000 claims 1
- 108010051081 dopachrome isomerase Proteins 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 230000000415 inactivating effect Effects 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 108010042121 probasin Proteins 0.000 claims 1
- 208000023958 prostate neoplasm Diseases 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
- 230000002463 transducing effect Effects 0.000 claims 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US60400904P | 2004-08-25 | 2004-08-25 | |
| US11/201,384 US20060062764A1 (en) | 2004-08-25 | 2005-08-11 | Fiber-modified adenoviral vectors for enhanced transduction of tumor cells |
| PCT/US2005/030196 WO2006026331A2 (en) | 2004-08-25 | 2005-08-25 | Fiber-modified adenoviral vectors for enhanced transduction of tumor cells |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008510493A JP2008510493A (ja) | 2008-04-10 |
| JP2008510493A5 true JP2008510493A5 (enExample) | 2008-09-11 |
Family
ID=36000570
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007530107A Withdrawn JP2008510493A (ja) | 2004-08-25 | 2005-08-25 | 腫瘍細胞の形質導入強化のための線維改変アデノウイルスベクター |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20060062764A1 (enExample) |
| EP (1) | EP1791968A4 (enExample) |
| JP (1) | JP2008510493A (enExample) |
| CA (1) | CA2577470A1 (enExample) |
| WO (1) | WO2006026331A2 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070010016A1 (en) * | 2005-03-11 | 2007-01-11 | Mccelland Alan | Gene transfer with adenoviruses having modified fiber proteins |
| CA2680659C (en) * | 2007-03-14 | 2016-06-28 | Institut Catala D'oncologia | Adenovirus with mutations in the endoplasmic reticulum retention domain of the e3-19k protein and their use in cancer treatment |
| US10131921B2 (en) * | 2008-03-06 | 2018-11-20 | Mayo Foundation For Medical Education And Research | Single cycle replicating adenovirus vectors |
| EP2414385B1 (en) * | 2009-03-31 | 2015-04-22 | University of Washington | Compositions and methods for modulating the activity of complement regulatory proteins on target cells |
| SG11201400139PA (en) * | 2011-08-23 | 2014-06-27 | Nat Inst Biomedical Innovation | Conditionally replicating adenovirus |
| US9624476B2 (en) | 2011-08-23 | 2017-04-18 | National Institute Of Biomedical Innovation | Conditionally replicating adenovirus |
| US9267153B2 (en) | 2011-12-15 | 2016-02-23 | Washington University | Porcine knob xenotype chimeric adenoviral vector for dendritic cell infection |
| AU2013296919A1 (en) * | 2012-07-30 | 2015-01-22 | Alex Wah Hin Yeung | Cancer vaccine comprises tumor cells, an oncolytic virus vector and/or an immune checkpoint modulator |
| KR101429696B1 (ko) * | 2012-11-21 | 2014-08-13 | 국립암센터 | 안전성 및 항암활성이 증가된 재조합 아데노바이러스 및 이의 용도 |
| SG10202004535PA (en) * | 2013-04-18 | 2020-06-29 | Tilt Biotherapeutics Oy | Enhanced adoptive cell therapy |
| US20170037431A1 (en) * | 2014-05-01 | 2017-02-09 | University Of Washington | In vivo Gene Engineering with Adenoviral Vectors |
| WO2016106178A1 (en) * | 2014-12-24 | 2016-06-30 | The Uab Research Foundation, Inc. | Multitargeting onocolytic adenovirus, methods of use, and methods of making |
| WO2017156349A1 (en) * | 2016-03-10 | 2017-09-14 | Cold Genesys, Inc. | Methods of treating solid or lymphatic tumors by combination therapy |
| JP2020516590A (ja) | 2017-04-14 | 2020-06-11 | コールド ジェネシス， インコーポレイテッド | 膀胱癌の治療方法 |
| WO2019117632A1 (ko) * | 2017-12-13 | 2019-06-20 | 한양대학교 산학협력단 | 재조합 아데노바이러스 및 이를 포함하는 줄기세포 |
| US20220111044A1 (en) * | 2019-01-29 | 2022-04-14 | Children's National Medical Center | Whole cell tumor vaccines and methods of use therof |
| US11149286B1 (en) | 2020-08-17 | 2021-10-19 | Mayo Foundation For Medical Education And Research | Adenovirus vectors and methods for using adenovirus vectors |
| US20250345414A1 (en) * | 2021-08-06 | 2025-11-13 | Theravax, Inc. | Adenoviral vector-based vaccine for emerging viruses |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US560843A (en) * | 1896-05-26 | Ningham | ||
| US5078996A (en) * | 1985-08-16 | 1992-01-07 | Immunex Corporation | Activation of macrophage tumoricidal activity by granulocyte-macrophage colony stimulating factor |
| US5098702A (en) * | 1986-04-09 | 1992-03-24 | Cetus Corporation | Combination therapy using interleukin-2 and tumor necrosis factor |
| US5637483A (en) * | 1991-10-04 | 1997-06-10 | Whitehead Institute For Biomedical Research | Irradiated tumor cell vaccine engineered to express GM-CSF |
| US5904920A (en) * | 1991-10-04 | 1999-05-18 | Whitehead Institute For Biomedical Research | Regulation of systemic immune responses utilizing cytokines and antigens |
| US5846945A (en) * | 1993-02-16 | 1998-12-08 | Onyx Pharmaceuticals, Inc. | Cytopathic viruses for therapy and prophylaxis of neoplasia |
| US5543328A (en) * | 1993-08-13 | 1996-08-06 | Genetic Therapy, Inc. | Adenoviruses having modified fiber proteins |
| US5698443A (en) * | 1995-06-27 | 1997-12-16 | Calydon, Inc. | Tissue specific viral vectors |
| US6312699B1 (en) * | 1994-03-28 | 2001-11-06 | Uab Research Foundation | Ligands added to adenovirus fiber |
| US5846782A (en) * | 1995-11-28 | 1998-12-08 | Genvec, Inc. | Targeting adenovirus with use of constrained peptide motifs |
| US5559099A (en) * | 1994-09-08 | 1996-09-24 | Genvec, Inc. | Penton base protein and methods of using same |
| US5962311A (en) * | 1994-09-08 | 1999-10-05 | Genvec, Inc. | Short-shafted adenoviral fiber and its use |
| US5998205A (en) * | 1994-11-28 | 1999-12-07 | Genetic Therapy, Inc. | Vectors for tissue-specific replication |
| US6127525A (en) * | 1995-02-21 | 2000-10-03 | Cornell Research Foundation, Inc. | Chimeric adenoviral coat protein and methods of using same |
| US5770442A (en) * | 1995-02-21 | 1998-06-23 | Cornell Research Foundation, Inc. | Chimeric adenoviral fiber protein and methods of using same |
| PT833934E (pt) * | 1995-06-15 | 2005-02-28 | Crucell Holland Bv | Sistemas de empacotamento para adenovivrus recombinente humano destinados a terapia genetica |
| US6033674A (en) * | 1995-12-28 | 2000-03-07 | Johns Hopkins University School Of Medicine | Method of treating cancer with a tumor cell line having modified cytokine expression |
| US6277368B1 (en) * | 1996-07-25 | 2001-08-21 | The Regents Of The University Of California | Cancer immunotherapy using autologous tumor cells combined with cells expressing a membrane cytokine |
| US5922315A (en) * | 1997-01-24 | 1999-07-13 | Genetic Therapy, Inc. | Adenoviruses having altered hexon proteins |
| US6432700B1 (en) * | 1997-03-03 | 2002-08-13 | Cell Genesys, Inc. | Adenovirus vectors containing heterologous transcription regulatory elements and methods of using same |
| EP1053301B1 (en) * | 1998-02-02 | 2004-04-21 | The Johns Hopkins University School Of Medicine | A universal immunomodulatory cytokine-expressing bystander cell line and related compositions and methods of manufacture and use |
| US6900049B2 (en) * | 1998-09-10 | 2005-05-31 | Cell Genesys, Inc. | Adenovirus vectors containing cell status-specific response elements and methods of use thereof |
| AU767975B2 (en) * | 1998-09-11 | 2003-11-27 | Genvec, Inc. | Alternatively targeted adenovirus |
| WO2001021216A1 (en) * | 1999-09-24 | 2001-03-29 | The Uab Research Foundation | Capsid-modified recombinant adenovirus and methods of use |
| US6692736B2 (en) * | 2000-03-24 | 2004-02-17 | Cell Genesys, Inc. | Cell-specific adenovirus vectors comprising an internal ribosome entry site |
| DE60138403D1 (de) * | 2000-09-26 | 2009-05-28 | Crucell Holland Bv | Adenovirale vektoren für die übertragung von genen in zellen der skelettmuskulatur oder myoblasten |
| IL152420A0 (en) * | 2001-02-23 | 2003-05-29 | Novartis Ag | Novel oncolytic adenoviral vectors |
| EP1377672A2 (en) * | 2001-02-23 | 2004-01-07 | Novartis AG | Vector constructs |
| JP4488290B2 (ja) * | 2002-01-24 | 2010-06-23 | ザ・スクリップス・リサーチ・インスティテュート | 効率的ターゲティングのためのファイバーシャフト変異 |
| EP1507593B1 (en) * | 2002-05-17 | 2007-10-17 | Gen-Probe Incorporated | Sample carrier having releasable locking mechanism |
| US7231839B2 (en) * | 2003-08-11 | 2007-06-19 | The Board Of Trustees Of The Leland Stanford Junior University | Electroosmotic micropumps with applications to fluid dispensing and field sampling |
| JP4561092B2 (ja) * | 2003-12-16 | 2010-10-13 | 日産自動車株式会社 | 車両用運転操作補助装置および車両用運転操作補助装置を備えた車両 |
-
2005
- 2005-08-11 US US11/201,384 patent/US20060062764A1/en not_active Abandoned
- 2005-08-25 CA CA002577470A patent/CA2577470A1/en not_active Abandoned
- 2005-08-25 EP EP05791237A patent/EP1791968A4/en not_active Withdrawn
- 2005-08-25 WO PCT/US2005/030196 patent/WO2006026331A2/en not_active Ceased
- 2005-08-25 JP JP2007530107A patent/JP2008510493A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008510493A5 (enExample) | ||
| JP4787936B2 (ja) | 癌処理への使用のためのキメラアデノウィルス | |
| Smith et al. | Adenovirus serotype 5 fiber shaft influences in vivo gene transfer in mice | |
| Glasgow et al. | Transductional and transcriptional targeting of adenovirus for clinical applications | |
| Hemminki et al. | Adenoviruses in oncology: a viable option? | |
| US20170190752A1 (en) | E1-minus adenoviruses and use thereof | |
| CA2428739A1 (en) | Complementing cell lines | |
| CA2525401A1 (en) | Cell specific replication-competent viral vectors comprising a self processing peptide cleavage site | |
| Relph et al. | Adenoviral strategies for the gene therapy of cancer | |
| JP2008510493A (ja) | 腫瘍細胞の形質導入強化のための線維改変アデノウイルスベクター | |
| Kim et al. | Antitumoral effects of recombinant adenovirus YKL-1001, conditionally replicating in α-fetoprotein-producing human liver cancer cells | |
| Kuhlmann et al. | Adenoviral gene therapy for pancreatic cancer: where do we stand? | |
| US20060228336A1 (en) | Human prolyl isomerase 1 (PIN 1) promoter and uses thereof | |
| Curiel et al. | Applications of viruses for cancer therapy | |
| Fang et al. | Adenovector-mediated cancer gene therapy | |
| Kangasniemi | Improving oncolytic adenoviral therapies for gastrointestinal cancers and tumor initiating cells | |
| Goldberg et al. | Adenoviral-Mediated Gene Therapy | |
| Li et al. | 615. Intravenous Gamma Globulins Pretreatment Enhances Adenoviral-Mediated Gene T Adenoviral-Mediated Gene T Adenoviral-Mediated Gene Transduction ransduction | |
| Gavrikova et al. | 971. New Generation Conditionally Replicative Adenovirus for Hormone-Refractory Prostate Cancer | |
| HK1179655B (en) | Chimeric adenoviruses for use in cancer treatment | |
| HK1205529B (en) | Chimeric adenoviruses for use in cancer treatment |